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ABSTRACT
Objective To empirically explore the level of agreement 
of the treatment hierarchies from different ranking metrics 
in network meta- analysis (NMA) and to investigate how 
network characteristics influence the agreement.
Design Empirical evaluation from re- analysis of NMA.
Data 232 networks of four or more interventions from 
randomised controlled trials, published between 1999 and 
2015.
Methods We calculated treatment hierarchies from 
several ranking metrics: relative treatment effects, 
probability of producing the best value  p
(
BV
)
  and the 
surface under the cumulative ranking curve (SUCRA). We 
estimated the level of agreement between the treatment 
hierarchies using different measures: Kendall’s τ  and 
Spearman’s  ρ  correlation; and the Yilmaz  τAP  and Average 
Overlap, to give more weight to the top of the rankings. 
Finally, we assessed how the amount of the information 
present in a network affects the agreement between 
treatment hierarchies, using the average variance, the 
relative range of variance and the total sample size over 
the number of interventions of a network.
Results Overall, the pairwise agreement was high 
for all treatment hierarchies obtained by the different 
ranking metrics. The highest agreement was observed 
between SUCRA and the relative treatment effect for both 
correlation and top- weighted measures whose medians 
were all equal to 1. The agreement between rankings 
decreased for networks with less precise estimates and 
the hierarchies obtained from  pBV   appeared to be the most 
sensitive to large differences in the variance estimates. 
However, such large differences were rare.
Conclusions Different ranking metrics address different 
treatment hierarchy problems, however they produced 
similar rankings in the published networks. Researchers 
reporting NMA results can use the ranking metric they 
prefer, unless there are imprecise estimates or large 
imbalances in the variance estimates. In this case 
treatment hierarchies based on both probabilistic and non- 
probabilistic ranking metrics should be presented.
INTRODUCTION
Network meta- analysis (NMA) is being 
increasingly used by policymakers and clini-
cians to answer one of the key questions in 
medical decision- making: ‘what treatment 
works best for the given condition?’.1 2 The 
relative treatment effects, estimated in NMA, 
can be used to produce ranking metrics: statis-
tical quantities measuring the performance 
of an intervention on the studied outcomes, 
thus producing a treatment hierarchy from 
the most preferable to the least preferable 
option.3 4
Despite the importance of treatment hier-
archies in evidence- based decision- making, 
various methodological issues related to the 
ranking metrics have been contested.5–7 This 
ongoing methodological debate focusses on 
the uncertainty and bias in a single ranking 
metric. Hierarchies produced by different 
ranking metrics are not expected to agree 
because ranking metrics differ. For example, 
a non- probabilistic ranking metric such as the 
treatment effect against a common compar-
ator considers only the mean effect (eg, the 
point estimate of the odds ratio (OR)) and 
ignores the uncertainty with which this is 
estimated. In contrast, the probability that a 
treatment achieves a specific rank (a probabi-
listic ranking metric) considers the entire esti-
mated distribution of each treatment effect. 
However, it is important to understand why 
and how rankings based on different metrics 
differ.
There are network characteristics that 
are expected to influence the agreement of 
Strengths and limitations of this study
 ► To our knowledge, this is the first empirical study 
exploring the level of agreement of the treatment hi-
erarchies from different ranking metrics in network 
meta- analysis (NMA).
 ► The study also explores how agreement is influ-
enced by network characteristics.
 ► More than 200 published NMAs were re- analysed 
and three different ranking metrics calculated using 
both frequentist and Bayesian approaches.
 ► Other potential factors not investigated in this study 
could influence the agreement between hierarchies.
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treatment hierarchies from different ranking metrics, such 
as the precision of the included studies and their distribu-
tion across treatment comparisons.4 8 Larger imbalances 
in precision in the estimation of the treatment effects 
affects the agreement of the treatment hierarchies from 
probabilistic ranking metrics, but it is currently unknown 
whether in practice these imbalances occur and whether 
they should inform the choice between different ranking 
metrics. To our knowledge, no empirical studies have 
explored the level of agreement of treatment hierarchies 
obtained from different ranking metrics, or examined 
the network characteristics likely to influence the level 
of agreement. Here, we empirically evaluated the level of 
agreement between ranking metrics and examined how 
the agreement is affected by network features. The article 
first describes the methods for the calculation of ranking 
metrics and of specific measures to assess the agreement 
and to explore factors that affects it, respectively. Then, 
a network featuring one of the explored factors is shown 
as an illustrative example to display differences in treat-
ment hierarchies from different ranking metrics. Finally, 
we present the results from the empirical evaluation and 
discuss their implications for researchers undertaking 
NMA.
METHODS
Data
We re- analysed networks of randomised controlled trials 
from a database of articles published between 1999 and 
2015, including at least four treatments; details about 
the search strategy and inclusion/exclusion criteria can 
be found in.9 10 We selected networks reporting arm- level 
data for binary or continuous outcomes. The database is 
accessible in the nmadb R package.11
Re-analysis and calculation of ranking metrics
All networks were re- analysed using the relative treat-
ment effect that the original publication used: OR, risk 
ratio (RR), standardised mean difference (SMD) or 
mean difference (MD). We estimated relative effects 
between treatments using a frequentist random- effects 
NMA model using the netmeta R package.12 For the 
networks reporting ORs and SMDs we re- analysed them 
also using Bayesian models using self- programmed NMA 
routines in JAGS (https:// github. com/ esm- ispm- unibe- 
ch/ NMAJags). To obtain probabilistic ranking metrics 
in a frequentist setting, we used parametric bootstrap 
by producing 1000 data sets from the estimated relative 
effects and their variance- covariance matrix. By averaging 
over the number of simulated relative effects we derived 
the probability of treatment  i to produce the best value
 pi,BV : = pi,1 = P
(
µij > 0 ∀ j ∈ T
)
 
where  µij  is the estimated mean relative effect of treat-
ment  i against treatment  j  out of a set T of T  competing 
treatments. We will refer to this as  pBV  . This ranking metric 
indicates how likely a treatment is to produce the largest 
values for an outcome (or smallest value, if the outcome is 
harmful). We also calculated the surface under the cumu-
lative ranking curve ( SUCRAF )3
 SUCRAi =
T−1∑
r=1
ci,r
T−1  
where 
 
ci,r =
r∑
v=1
pi,v
 
 are the cumulative probabilities that 
treatment  i will produce an outcome that is among the 
 r best values (or that it outperforms  T− r treatments). 
SUCRA, unlike  pBV  , also considers the probability of a 
treatment to produce unfavourable outcome values. 
Therefore, the treatment with the largest SUCRA value 
represents the one that outperforms the competing treat-
ments in the network, meaning that overall it produces 
preferable outcomes compared with the others. We also 
obtained SUCRAs within a Bayesian framework ( SUCRAB
 ).
To obtain the non- probabilistic ranking metric we fitted 
an NMA model and estimated related treatment effects. 
To obtain estimates for all treatments we reparametrise 
the NMA model so that each treatment is compared with 
a fictional treatment of average performance.13 14 The 
estimated relative effects against a fictional treatment F of 
average efficacy  ̂µiF   represent the ranking metric and the 
corresponding hierarchy is obtained simply by ordering 
the effects from the largest to the smallest (or in ascending 
order, if the outcome is harmful). The resulting hierarchy 
is identical to that obtained using relative effects from the 
conventional NMA model, irrespective of the reference 
treatment. In the rest of the manuscript, we will refer to 
this ranking metric simply as relative treatment effect.
Agreement between ranking metrics
To estimate the level of agreement between the treatment 
hierarchies obtained using the three chosen ranking 
methods we employed several correlation and similarity 
measures.
To assess the correlation between ranking metrics we 
used Kendall’s τ  15 and the Spearman’s  ρ .
16 Both Kendall’s 
 τ  and Spearman’s  ρ  give the same weight to each item in 
the ranking. In the context of treatment ranking, the top 
of the ranking is more important than the bottom. We 
therefore also used a top- weighted variant of Kendall’s τ
 , Yilmaz  τAP ,17 which is based on a probabilistic interpre-
tation of the average precision measure used in informa-
tion retrieval18 (see online supplementary appendix).
The measures described so far can only be considered 
for conjoint rankings, that is, for lists where each item 
in one list is also present in the other list. Rankings are 
non- conjoint when a ranking is truncated to a certain depth 
k with such lists called top- k rankings. We calculated the 
Average Overlap,19 20 a top- weighted measure for top- k 
rankings that considers the cumulative intersection (or 
overlap) between the two lists and averages it over a spec-
ified depth (cut- off point) k (see online supplementary 
appendix for details). We calculated the Average Overlap 
between pairs of rankings for networks with at least six 
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treatments (139 networks) for a depth k equal to half the 
number of treatments in the network,  k =
T
2   (or  
(
T − 1
)
/2  
if T is an odd number).
We calculated the four measures described above to 
assess the pairwise agreement between the three ranking 
metrics within the frequentist setting and summarised 
them for each pair of ranking metrics and each agreement 
measure using the median and the first and third quar-
tiles. The hierarchy according to  SUCRAB was compared 
with that of its frequentist equivalent to check how often 
the two disagree.
Influence of network features on the rankings agreement
The main network characteristic considered was the 
amount of information in the network (reflected in the 
precision of the estimates). Therefore, for each network 
we calculated the following measures of information:
 ► The average variance, calculated as the mean of 
the variances of the estimated treatment effects 
 mean
(
SE2
)
 , to show how much information is present 
in a network altogether;
 ► The relative range of variance, calculated as 
 
max SE2−min SE2
max SE2  , to describe differences in information 
about each intervention within the same networks;
 ► The total sample size of a network over the number of 
interventions.
These measures are presented in scatter plots against 
the agreement measurements for pairs of ranking metrics.
All the codes for the empirical evaluation are avail-
able at https:// github. com/ esm- ispm- unibe- ch/ 
rankingagreement
Patient and public involvement
Patients and the public were not involved in this study.
ILLUSTRATIVE EXAMPLE
To illustrate the impact of the amount of information on 
the treatment hierarchies from different ranking metrics, 
we used a network of nine antihypertensive treatments 
for primary prevention of cardiovascular disease that 
presents large differences in the precision of the esti-
mates of overall mortality.21 The network graph and forest 
plot of relative treatment effects of each treatment versus 
placebo are presented in figure 1. The relative treatment 
effects reported are RR estimated using a random effects 
NMA model.
Table 1 shows the treatment hierarchies obtained 
using the three ranking metrics described above. The 
highest overall agreement is between hierarchies from 
the  SUCRAF and the relative treatment effect as shown by 
both correlation (Spearman’s  ρ  = 0.93, Kendall’s τ  = 0.87) 
and top- weighted measures (Yilmaz’s  τAP  = 0.87; Average 
Overlap=0.85). The level of agreement decreases when 
 SUCRAF and the relative treatment effect are compared 
with  pBV   rankings (Spearman’s  ρ  = 0.63 and  ρ  = 0.85, 
respectively). Agreement with  pBV   especially decreases 
when considering top ranks only (Average Overlap is 0.48 
for  pBV  vs  SUCRAF and 0.54 for  pBV   vs relative treatment 
effect). All agreement measures are presented in online 
supplementary table S1.
The reason for this disagreement is explained by the 
differences in precision in the estimated effects (figure 1). 
These RRs versus placebo range from 0.82 (diuretic/beta- 
blocker vs placebo) to 0.98 (beta- blocker vs placebo). All 
estimates are fairly precise except for the RR of conven-
tional therapy versus placebo whose 95% confidence 
interval (CI) extends from 0.21 to 3.44. This uncertainty 
in the estimation is due to the fact that conventional 
therapy is compared only with angiotensin receptor 
blockers (ARB) via a single study. This large difference 
in the precision of the estimation of the treatment effects 
mostly affects the  pBV   ranking, which disagrees the most 
with both of the other rankings. Consequently, the 
conventional therapy is in the first rank in the  pBV   hier-
archy (because of the large uncertainty) but only features 
in the third/fourth and sixth rank using the relative treat-
ment effects and  SUCRAF hierarchies, respectively.
To explore how the hierarchies for this network would 
change in case of increased precision, we reduced the 
standard error (SE) of the conventional versus ARB 
Figure 1 (Left panel) Network graph of network of nine antihypertensive treatments for primary prevention of cardiovascular 
disease. Line width is proportional to inverse standard error of random effects model comparing two treatments. (Right panel) 
Forest plots of relative treatment effects of overall mortality for each treatment versus placebo. ACE, Angiotensin Converting 
Enzyme; ARB, angiotensin receptor blockers; CCB, calcium channelblockers; RR, risk ratio.
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treatment effect from the original 0.7 to a fictional value 
of 0.01 resulting in a CI 0.77 to 0.96. The columns in the 
right- hand side of table 1 display the three equivalent 
rankings after the SE reduction. The conventional treat-
ment has moved up in the hierarchy according to  SUCRAF 
and moved down in the one based on  pBV  , as expected. 
The treatment hierarchies obtained from the  SUCRAF and 
the relative treatment effect are now identical (conven-
tional and ARB share the 3.5 rank because they have 
the same effect estimate) and the agreement with the 
 pBV   rankings also improved ( pBV   vs  SUCRAF Spearman’s 
 ρ  = 0.89, Average Overlap=0.85;  pBV   vs relative treatment 
effect Spearman’s  ρ  = 0.91, Average Overlap=0.94; online 
supplementary table S1).
RESULTS
A total of 232 networks were included in our data set. 
Their characteristics are shown in table 2.
The majority of networks (133 NMAs, 57.3%) did not 
report any ranking metrics in the original publication. 
Among those which used a ranking metric to produce 
a treatment hierarchy, the probability of being the best 
was the most popular metric followed by the SUCRA with 
35.8% and 6.9% of networks reporting them, respectively.
Table 3 presents the medians and quartiles for each 
similarity measures. All hierarchies showed a high level 
of pairwise agreement, although the hierarchies obtained 
from the  SUCRAF and the relative treatment effect 
presented the highest values for both unweighted and 
with top- weighted measures (all measures’ median equals 
1). Only four networks (less than 2%) had a Spearman’s 
correlation between  SUCRAF and the relative treatment 
effect less than 90% (not reported). The correlation 
becomes less between the  pBV   rankings and those obtained 
from the other two ranking metrics with Spearman’s  ρ  
median decreasing to 0.9 and Kendall’s τ  decreasing to 
0.8. The Spearman’s correlation between these rankings 
was less than 90% in about 50% of the networks (in 116 
and 111 networks for  pBV   vs  SUCRAF and  pBV   vs relative 
effect, respectively; results not reported). The pairwise 
agreement between the  pBV   rankings and the other rank-
ings also decreased when considering only top ranks ( pBV   
vs  SUCRAF Yilmaz’s  τAP  = 0.77, Average Overlap=0.83;  pBV   
vs relative treatment effect Yilmaz’s  τAP  = 0.79, Average 
Overlap=0.88).
The SUCRAs from frequentist and Bayesian settings 
( SUCRAF and  SUCRAB ) were compared in 126 networks 
(82 networks using the Average Overlap measure) as 
these reported OR and SMD as original measures. The 
relevant rankings do not differ much as shown by the 
median values of the agreement measures all equal to 1 
and their narrow interquartile ranges (IQRs) (table 3). 
Nevertheless, a few networks showed a much lower 
agreement between the two SUCRAs. These networks 
provide posterior effect estimates for which the normal 
approximation is not optimal, some of which due to rare 
outcomes. Such cases were however uncommon as in only 
6% of the networks the Spearman’s correlation between 
and was less than 90%. Plots for the normal distributions 
from the frequentist setting and the posterior distribu-
tions of the log ORs for a network with a Spearman’s of 
0.6 between the two SUCRAs is available in online supple-
mentary figure S1.22
22
Figure 2 presents how Spearman’s  ρ  and the Average 
Overlap vary with the average variance of the relative 
Table 1 Example of treatment hierarchies from different ranking metrics for a network of nine antihypertensive treatment for 
primary prevention of cardiovascular disease
Treatment
Original data
Fictional data with increased precision for 
conventional treatment versus ARB
 pBV Ranks
 SUCRAF
 Ranks
Relative treatment 
effect ranks  pBV Ranks
 SUCRAF
 Ranks
Relative treatment 
effect ranks
Conventional 1 6 3.5 3 4 3.5
Diuretic/beta- blocker 2 1 1 1 1 1
ARB 3 3 3.5 4.5 3 3.5
CCB 4 2 2 2 2 2
Alpha- blocker 5 7 7 4.5 7 7
ACE- inhibitor 6 4 5 6.5 5 5
Diuretic 7 5 6 6.5 6 6
Placebo 8.5 9 9 8.5 9 9
Beta- blocker 8.5 8 8 8.5 8 8
Relative treatment effect stands for the relative treatment effect against fictional treatment of average performance. The first three rankings 
from the left- hand side are obtained using the original data; the equivalent three rankings on the right- hand side are produced by reducing the 
standard error of the conventional versus ARB treatment effect from 0.7 to a fictional value of 0.01.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; pBV 
, probability of producing the best value; SUCRAF, surface under the cumulative ranking curve (calculated in frequentist setting).
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treatment effect estimates in a network (scatter plots for 
the Kendall’s τ  and the Yilmaz’s  τAP  are available in online 
supplementary figure S2). The treatment hierarchies 
agree more in networks with more precise estimates (left 
hand side of the plots).
The association between Spearman’s  ρ  or Average 
Overlap and the relative range of variance in a network 
(here transformed to a double logarithm of the inverse 
values) are displayed in figure 3. On the right- hand side of 
each plot we can find networks with smaller differences in 
the precision of the treatment effect estimates. Treatment 
hierarchies for these networks show a larger agreement 
than for those with larger differences in precision. The 
plots of the impact of the relative range of variance on all 
measures are available in online supplementary figure S3.
The total sample size in a network over the number of 
interventions has a similar impact on the level of agree-
ment between hierarchies. This confirms that the agree-
ment between hierarchies increases for networks with 
a large total sample size compared with the number of 
treatments and, more generally, it increases with the 
amount of information present in a network (online 
supplementary figure S4).
DISCUSSION
Our empirical evaluation showed that in practice the 
level of agreement between treatment hierarchies is 
overall high for all ranking metrics used. The agreement 
between treatment hierarchies from  SUCRA and relative 
treatment effect was very often perfect. The agreement 
between the rankings from  SUCRA or relative treatment 
effect and the ranking from  pBV   was good but decreased 
when the top- ranked interventions are of interest. The 
agreement is higher for networks with precise estimates 
and small imbalances in precision.
Simulation studies6 23 using theoretical examples have 
shown the importance of accounting for the precision in 
the estimation of the treatment effects when a hierarchy 
is to be obtained. However, we show that cases of extreme 
imbalance in the precision of the treatment effects are 
rather uncommon.
Table 2 Characteristics of the 232 NMAs included in the 
re- analysis
Characteristics of 
networks Median IQR
Median number of 
treatments compared
6 (5 to 9)
Median number of 
studies included
19 (12 to 34)
Median total sample 
size
6100 (2514 to 17264)
  Number of 
NMAs
%
Beneficial outcome 97 41.8%
Dichotomous outcome 185 79.7%
Continuous outcome 47 20.3%
Published before 2010 42 18.1%
Ranking metric used in original publication (non- exclusive)
  Probability of 
producing the best 
value
83 35.8%
  Rankograms 7 3%
  Median or mean rank 3 1.3%
  SUCRA 16 6.9%
  Other 2 0.9%
None 133 57.3%
Published in general 
medicine journals*
125 53.9%
Published in health 
services research 
journals†
3 1.3%
Published in specialty 
journals
104 44.8%
*Includes the categories Medicine, General and Internal, 
Pharmacology and Pharmacy, Research and Experimental, Primary 
Healthcare.
†Includes the categories Healthcare Sciences and Services, Health 
Policy and Services.
IQR, interquartile range; NMA, network meta- analysis; SUCRA, 
surface under the cumulative ranking curve.
Table 3 Pairwise agreement between treatment hierarchies obtained from the different ranking metrics measured by 
Spearman  ρ , Kendall τ  , Yilmaz  τ AP  and Average Overlap
 pBV vs SUCRAF 
 SUCRAF versus relative treatment 
effect
 pBV versus relative treatment 
effect
 SUCRAF
 versus SUCRAB 
Spearman ρ 0.9 (0.8 to 0.96) 1 (0.99 to 1) 0.9 (0.8 to 0.97) 1 (0.98 to 1)
Kendallτ  0.8 (0.67 to 0.91) 1 (0.95 to 1) 0.8 (0.69 to 0.91) 1 (0.93 to 1)
Yilmaz τ AP 0.78 (0.6 to 0.9) 1 (0.93 to 1) 0.79 (0.65 to 0.9) 1 (0.93 to 1)
Average Overlap 0.85 (0.72 to 0.96) 1 (0.91 to 1) 0.88 (0.79 to 1) 1 (0.94 to 1)
Medians, first and third quartiles are reported.
Relative treatment effect stands for the relative treatment effect against fictional treatment of average performance.
PBV, probability of producing the best value; SUCRAB, surface under the cumulative ranking curve (calculated in Bayesian setting); SUCRAF, 
surface under the cumulative ranking curve (calculated in frequentist setting).
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Several factors can be responsible for imprecision in the 
estimation of the relative treatment effects in a network:
 ► Large sampling error, determined by a small sample 
size, small number of events or a large standard 
deviation;
 ► Poor connectivity of the network, when only a few 
links and few closed loops of evidence connect the 
treatments;
 ► Residual inconsistency;
 ► Heterogeneity in the relative treatment effects.
Random- effects models tend to provide relative treat-
ment effects with similar precision as heterogeneity 
increases. In contrast, in the absence of heterogeneity 
when fixed- effects models are used, the precision of the 
effects can vary a lot according to the amount of data 
available for each intervention. In the latter case, the 
ranking metrics are likely to disagree. Also, the role of 
precision in ranking disagreement is more pronounced 
in cases where the interventions have similar effects.
Our results also confirm that a treatment hierarchy can 
differ when the uncertainty in the estimation is incorpo-
rated into the ranking metric (by using, for example, a 
probabilistic metric rather than ranking the point esti-
mate of the mean treatment effect)8 24 and that rankings 
from the  pBV   seem to be the most sensitive to differences 
in precision in the estimation of treatment effects. We 
showed graphically that the agreement is less in networks 
with more uncertainty and with larger imbalances in the 
variance estimates. However, we also found that such large 
imbalances do not occur frequently in real data and in 
the majority of cases the different treatment hierarchies 
have a relatively high agreement.
We acknowledge that there could be other factors 
influencing the agreement between hierarchies that we 
did not explore, such as the chosen effect measures.25 
However, we think it is unlikely that such features play 
a big role in ranking agreement unless assumptions are 
violated or data in the network is sparse.26 Adjustment via 
network meta- regression (for example, for risk of bias or 
small- study effects) might impact on the ranking of treat-
ments not only by changing the point estimate but also 
by altering the total precision and the imbalance in the 
precision of the estimated treatment effects. We did not 
investigate the agreement between treatment hierarchies 
obtained from such adjusted analyses. We also did not 
explore non- methodological characteristics for networks 
with larger disagreement but we believe these charac-
teristics are a proxy for the amount of information in a 
network, which is the main factor affecting the agreement 
between ranking metrics. For example, in some specific 
fields there are few or small randomised trials (eg, 
surgery) and, as a consequence, the resulting networks 
will have less information. Also, smaller (hence more 
imprecise) networks might be published more often in 
journal with lower impact factor and get less citations 
than large and precise networks.
To our knowledge, this is the first empirical study 
assessing the level of agreement between treatment 
Figure 2 Scatter plots of the average variance in a network and the pairwise agreement between hierarchies from different 
ranking metrics. The average variance is calculated as the mean of the variances of the estimated treatment effects and 
describes the average information present in a network. More imprecise network are on the right- hand side of the plots. 
Spearman  ρ  (top row) and Average Overlap (bottom row) values for the pairwise agreement between  pBV   and SUCRAF (first 
column), SUCRAF and relative treatment effect (second column), pBV   and relative treatment effect (third column). Purple line: 
cubic smoothing spline with five degrees of freedom. pBV, probability of producing the best value; SUCRAF, surface under the 
cumulative ranking curve (calculated in frequentist setting). copyright.
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hierarchies from ranking metrics in NMA and it provides 
further insights into the properties of the different 
methods. In this context, it is important to stress that 
neither the objective nor the findings of this empirical 
evaluation imply that a hierarchy for a particular metric 
works better or is more accurate than one obtained from 
another ranking metric. The reason why this sort of 
comparison cannot be made is that each ranking metric 
address a specific treatment hierarchy problem. For 
example, the  SUCRA ranking addresses the issue of which 
treatment outperforms most of the competing interven-
tions, while the ranking based on the relative treatment 
effect gives an answer to the problem of which treat-
ment is associated with the largest average effect for the 
outcome considered.
Our study shows that, despite theoretical differences 
between ranking metrics and some extreme exam-
ples, they produce very similar treatment hierarchies in 
published networks. In networks with large amount of 
data for each treatment, hierarchies based on SUCRA 
or the relative treatment effect will almost always agree. 
Large imbalances in the precision of the treatment effect 
estimates do not occur often enough to motivate a choice 
between the different ranking metrics. Therefore, our 
advice to researchers presenting results from NMA is the 
following: if the NMA estimated effects are precise, to use the 
ranking metric they prefer; if at least one NMA estimated 
effect is imprecise, to refrain from making bold statements 
about treatment hierarchy and present hierarchies from 
both probabilistic (eg, SUCRA or rank probabilities) and 
non- probabilistic metrics (eg, relative treatments effects).
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Figure 3 Scatter plots of the relative range of variance in a network and the pairwise agreement between hierarchies from 
different ranking metrics. The relative range of variance, calculated as  
maxSE2−minSE2
maxSE2  , indicates how much the information differs 
between interventions in the same networks. Networks with larger differences in variance are on the left- hand side of the plots. 
Spearman  ρ  (top row) and Average Overlap (bottom row) values for the pairwise agreement between  pBV   and SUCRAF (first 
column), SUCRAF and relative treatment effect (second column),  pBV   and relative treatment effect (third column). Purple line: 
cubic smoothing spline with five degrees of freedom. pBV, probability of producing the best value; ; SUCRAF, surface under the 
cumulative ranking curve (calculated in frequentist setting).
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